PTHS
Pelthos Therapeutics Inc.
There isn't enough reported data to score PTHS yet.
PTHS Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Weak | |
| Unavailable | |
| Unavailable |
PTHS's profitability is currently weak. There isn't enough data to rate its revenue, cash flow and balance sheet.
PTHS PE Valuation
PTHS has no meaningful PE right now: it lost money over the past year.
PTHS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Low |
Analysts expect PTHS's losses to shrink, with revenue growing. However, they disagree widely on these estimates.
PTHS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$25.39 | -$8.71 |
| Q2 2026 | -$28.65 | -$14.37 |
| Q1 2026 | -$27.41 | -$15.41 |
| Q4 2025 | -$23.04 | -$8.74 |
| Q3 2025 | -$16.68 | +$1.69 |
PTHS lost $25.39 per share over the past year, a bigger loss than the year before.
PTHS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $15.4M | +108% |
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -63% | +145 points |
| Q2 2026 | -111% | N/A |
| Q1 2026 | -120% | N/A |
| Q4 2025 | -73% | N/A |
| Q3 2025 | -207% | N/A |
PTHS's operating margin was −63% last quarter, up 144 points from the same quarter a year ago.
PTHS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$5.2M | +$10M |
| Q2 2026 | -$7.7M | -$7.2M |
| Q1 2026 | -$13.3M | -$12.7M |
| Q3 2025 | -$15.3M | -$15.1M |
| Q2 2025 | -$447.1K | +$2.5M |
| Q1 2025 | -$632.1K | +$1.4M |
| Q4 2024 | -$670.3K | -$313.5K |
PTHS has burned cash in almost every quarter: −$41M over the past year, against −$2M the year before.
PTHS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +9.1% | +323K shares |
| 1 year | +503% | +3.2M shares |
PTHS has 4M diluted shares, up 503% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2024 | $75,000 |
| Q3 2024 | $75,000 |
| Q2 2024 | — |
| Q1 2024 | $91,512 |
| Q4 2023 | — |
PTHS Net Leverage
PTHS's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
PTHS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 20.4 | Oversold |
| Stochastic | 1.5 | Oversold |
PTHS's weekly RSI is 20 (oversold) and its Stochastic is 2 (oversold).
PTHS PE vs Healthcare Sector
PTHS has no meaningful PE right now: it lost money over the past year.
PTHS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $15.9 | 49% below |
| 20 week MA | $21.8 | 63% below |
| 50 week MA | $23.6 | 66% below |
PTHS is in a downtrend: it's below all three of its weekly moving averages, and 66% below its 50-week average.
PTHS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2025 | $13.5 | $25.7 | +90% |
| 2026 YTD | $25.7 | $8.03 | -69% |
PTHS has finished every year since 2025 higher, and it's down 69% so far in 2026.